1 week Ago By Defense World Staff
Vanguard Group Inc. cut its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 0.
7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,848,923 shares of the company’s stock after selling 38,287 shares during the period. Vanguard Group Inc.
owned approximately 5.80% of Day One Biopharmaceuticals worth $74,106,000 as of its most recent SEC filing. A number of other hedge funds also recently added to or reduced their stakes in the stock.
R Squared Ltd purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth approximately $31,000. E Fund Management Co. Ltd.
purchased a new position in Day One Biopharmaceuticals during the 4th quarter worth $143,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Day One Biopharmaceuticals in the 4th quarter worth $150,000. XTX Topco Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter worth $178,000.
Finally, Teacher Retirement System of Texas boosted its holdings in shares of Day One Biopharmaceuticals by 20.9% in the fourth quarter. Teacher Retirement System of Texas now owns 17,825 shares of the company’s stock valued at $226,000 after acquiring an additional 3,086 shares in the last quarter.
87.95% of the stock is owned by institutional investors and hedge funds. Day One Biopharmaceuticals Stock Down 7.
0 %NASDAQ:DAWN opened at $6.76 on Friday. The company has a market capitalization of $685.
16 million, a PE ratio of -6.56 and a beta of -1.24.
Day One Biopharmaceuticals, Inc. has a 52-week low of $6.41 and a 52-week high of $18.
07. The stock has a fifty day simple moving average of $9.44 and a 200-day simple moving average of $12.
09. Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.
69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34).
The business had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million.
As a group, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.
Analyst Upgrades and DowngradesSeveral research analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th.
JPMorgan Chase & Co. reduced their price target on Day One Biopharmaceuticals from $39.00 to $34.
00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th.
HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Finally, Bank of America reduced their price objective on shares of Day One Biopharmaceuticals from $28.
00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock.
According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $32.29.
Get Our Latest Research Report on DAWNInsider Activity at Day One BiopharmaceuticalsIn other news, CEO Jeremy Bender sold 12,048 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.
08. Following the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at $1,531,059.40.
This represents a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Also, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.
16. Following the sale, the general counsel now directly owns 39,602 shares in the company, valued at approximately $473,639.92.
The trade was a 10.50 % decrease in their position. The disclosure for this sale can be found here.
In the last 90 days, insiders have sold 21,064 shares of company stock valued at $251,925. 8.40% of the stock is owned by corporate insiders.
Day One Biopharmaceuticals Company Profile (Free Report)Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.Further ReadingFive stocks we like better than Day One BiopharmaceuticalsInvesting In Preferred Stock vs.
Common StockJoby Aviation: Operational Momentum vs. Market SentimentInsider Buying Explained: What Investors Need to KnowBroadcom’s Big Outperformance Shows Strength Amid Tariff DeclineWhat is a Secondary Public Offering? What Investors Need to KnowCarvana: Can Turnaround Strength Outdrive Market Headwinds?.
